Intelligence

#Cancer #Cancer research #Collaboration #Innovation

Cancer Research UK and University of Edinburgh start-up boost 

A University of Edinburgh business-support programme has partnered with Cancer Research UK to help build startup companies focused on tackling cancer.  The charity will fund up to ten participants in the second round of the university’s Data-Driven Entrepreneurship (DDE) Venture Builder Incubator, which supports postgraduate students, postdoctoral researchers and academic staff… Read More

#Cancer Research #News #Start-up Zone #Trending News

#Biopharmaceuticals #Cell culture

Batch-to-batch consistency: premium grade bioactive proteins

From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced to the highest standards… Read More

#Intelligence #Resources

#Biopharmaceuticals #Informatics

Weighing in Compliance with European Pharmacopoeia Chapter 2.1.7

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.   Balances for Analytical Purposes aims to ensure quality control of… Read More

#Intelligence #Resources

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Biotechnology #Life sciences

Lithuania eyes major window of opportunity in life sciences 

Enterprise Lithuania and the Lithuanian Biotechnology Association has announced that in 2020, the Lithuanian biotechnology sector grew by a record 87% and accounted for 2.5% of the Baltic nation’s GDP. Industry leaders gathering at the upcoming Life Sciences Baltics forum are now calling for more international collaborations, increased investment… Read More

#Market Reports #News #Trending News

#Biopharmaceuticals #Informatics

Cubis Laboratory Balances in Vaccine Research and Development

Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save millions of lives. Along the continuous emergence of new diseases and… Read More

#Intelligence #Resources

#Biotechnology #Clinical trials #CRISPR #Market reporting #Therapeutics

Report predicts trends and forecasts for CRISPR 

The “CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030” report has been added to ResearchAndMarkets.com’s offering.  The report features a study of the current market landscape and future opportunity for the players involved in the… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected… Read More

#News #Trends & Analysis

#Business #Pharmaceuticals

South Korea’s drug pricing could boost pharma innovation, says data 

South Korea is supporting innovative pharmaceutical companies by revising the health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData.  According to GlobalData, the pharmaceutical market in South Korea is estimated to grow at a… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#Biotechnology #Infographic

Infographic: Biotech hot spots in a fragmented European landscape 

McKinsey has mapped out 1,382 biotechs based in Europe and some interesting themes emerged, showing how European biotechs have established a position of strength from which to enter the industry’s next act. Over the past three years, Europe’s biotech industry has made meaningful progress on attracting capital and bringing products to market. … Read More

#Market Reports #News #Trends & Analysis

#Biotherapeutics #Gene therapy #Global data

Gene therapies could revolutionise CVDs, data says 

Gene therapies could revolutionise the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The data and analytics company notes that there are currently 87* CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life.  Fiona Chisholm, Pharma… Read More

#Market Reports #News #Trends & Analysis

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Valneva begins submission to MHRA for its Covid-19 vaccine 

Valneva has begun a rolling submission for initial approval of its Covid-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials… Read More

#Covid-19 #News #Trends & Analysis

#Pharma #Pharmaceuticals #Therapeutics

Digital brain biomarker start-up appoints Acacia founder to board 

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments. Read More

#Business & Investment #News #Start-up Zone

#Biologics / Biotechnology #Covid-19 #HIV #In vivo #Therapeutics

Biotech start-up takes another stride toward flu cure 

Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.  The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with… Read More

#News #Start-up Zone

#Funding #Rare disease #Therapeutics

Angelini Pharma and Lumira Ventures launch the ALBF

Angelini Pharma and Lumira have launched the Angelini Lumira Biosciences Fund (ALBF), which has been established to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. The ALBF will be managed by Lumira Ventures and Angelini… Read More

#News #Start-up Zone